Dr. E. David Crawford spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Sunday, November 16, 2014 on “Risk of Renal and Cardiovascular Side Effects with ADT.”
Keywords: renal cell carcinoma (RCC), cardiovascular side effects, ADT
How to cite: Crawford, E. David. “Risk of Renal and Cardiovascular Side Effects with ADT” Grand Rounds in Urology. July 15015. Accessed Nov 2024. https://dev.grandroundsinurology.com/prostate-cancer-e-david-crawford-side-effects-withadt/.
References
Chawla LS, Amdur RL, Amodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011 Jun;79(12):1361-9.
http://www.ncbi.nlm.nih.gov/pubmed/21430640
Chen HF, Jeung EB, Stephenson M, et al. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999 Feb;84(2):743-50.
http://www.ncbi.nlm.nih.gov/pubmed/10022447
Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70.
http://www.ncbi.nlm.nih.gov/pubmed/16177006
Chung SD, Liu SP, Lin HC, et al. Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer. PLoS One. 2014 Jun 27;9(6).
http://www.ncbi.nlm.nih.gov/pubmed/24971988
Dansky HM, Charlton SA, Harper MM, et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4642-6.
http://www.ncbi.nlm.nih.gov/pubmed/9114044
Dixit VD, Yang H, Udhayakumar V, et al. Gonadotropin-releasing hormone alters the T helper cytokine balance in the pregnant rat. Biol Reprod. 2003 Jun;68(6):2215-21.
http://www.ncbi.nlm.nih.gov/pubmed/12606332
Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001 Apr;59(4):1498-509.
http://www.ncbi.nlm.nih.gov/pubmed/11260414
Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014 Dec;66(6):1101-8.
http://www.ncbi.nlm.nih.gov/pubmed/24440304
Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014 Apr;65(4):704-9.
http://www.ncbi.nlm.nih.gov/pubmed/23433805
Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 6;102(1):39-46.
http://www.ncbi.nlm.nih.gov/pubmed/19996060
Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013 Jul 17;310(3):289-96.
http://www.ncbi.nlm.nih.gov/pubmed/23860987
Molinari C, Battaglia A, Grossini E, et al. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol. 2002 Aug 15;543(Pt 1):365-72.
http://www.ncbi.nlm.nih.gov/pubmed/12181306
Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May;67(5):825-36.
http://www.ncbi.nlm.nih.gov/pubmed/25097095
Schiffl H, Lang SM. Current practice of conventional intermittent hemodialysis for acute kidney injury. Indian J Nephrol. 2013 Nov;23(6):395-402.
http://www.ncbi.nlm.nih.gov/pubmed/24339514
Schiffl H, Lang SM, Fischer R. Long-term outcomes of survivors of ICU acute kidney injury requiring renal replacement therapy: a 10-year prospective cohort study. Clin Kidney J. 2012 Aug;5(4):297-302.
http://www.ncbi.nlm.nih.gov/pubmed/25874084
Tanriverdi F, Gonzalez-Martinez D, Hu Y, et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005 Oct;142(1):103-10.
http://www.ncbi.nlm.nih.gov/pubmed/16178862
Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010 Jul 20;28(21):3448-56.
http://www.ncbi.nlm.nih.gov/pubmed/20567006
ABOUT THE AUTHOR
Researcher-physician E. David Crawford, MD, has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States.
He is currently a Professor of Urology at the University of California, San Diego, and emeritus distinguished endowed Professor of Surgery, Urology, and Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Anschutz Medical Campus in Aurora, Colorado. Dr. Crawford received his medical degree from the University of Cincinnati and his postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship at the University of California Medical Center in Los Angeles.
Dr. Crawford is an internationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular, prostate cancer. He has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone-refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 810 scientific articles, has published seven textbooks, authored over 60 book chapters, and provided more than 2,200 educational talks for patients and physicians.
In an effort to raise public awareness about prostate health, Crawford in 1989 founded the Prostate Conditions Education Council (PCEC). The non-profit organization is comprised of a consortium of leading physicians, health educators, scientists, and men's health advocates. PCEC's advocacy for free or low-cost prostate screening has affected the lives of millions of American men. He currently chairs the PCEC.
Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, the American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he has been a member of the Committee to Study Urologic Research Funding and the prostate cancer clinical trials subcommittee. Crawford served on the board of governors, the scientific advisory board of the Southwest Oncology Group, and was chairman of the Genitourinary Cancer Committee for 27 years. This group is the largest clinical trials group in the world.
Crawford's involvement in the national prostate cancer arena has been widely recognized. He has received many honors and awards, including the CAP Cure Annual Award for Scientific Presentation in 1999 In 1997, he was presented with a 'Freddie Award" at the AMA International Health and Medical Film Competition for the program, ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Crawford hosted with special guest, retired General Norman Schwarzkopf.
Crawford again won a prestigious 'Freddie Award" 5 years ago... He is a member of Best Doctors of America and was named Healthcare Provider of the Year in the Denver Metro area by the Denver Business Journal.
He has been recognized as one of the Best Doctors of America for the past two decades and is recognized as one of the top 20 urologists in the country, for men, by Men’s Health Magazine. In 2018 he received the honor of being named the Distinguished Alumnus of the Year from the University of Cincinnati School of Medicine. In May of 2019, he received the Presidential citation from the American Urological Association recognizing for his “tireless role in genitourinary cancer research that has benefited countless urologic cancer patients.” He accepted the position of Editor in Chief of Grand Rounds in Urology in June of 2019. In 2021, he was the recipient of the Merle Stringer, M.D. annual award for excellence in medicine by the Florida State Medical Association.